Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company BioCryst Pharmaceuticals Inc.
DescriptionSecond-generation kallikrein inhibitor
Molecular Target Kallikrein
Mechanism of ActionKallikrein inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAngioedema
Indication DetailsPrevent attacks in patients with hereditary angioedema (HAE)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today